These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 7822205)

  • 41. Colloidal, in vitro and in vivo anti-leishmanial properties of transfersomes containing paromomycin sulfate in susceptible BALB/c mice.
    Bavarsad N; Fazly Bazzaz BS; Khamesipour A; Jaafari MR
    Acta Trop; 2012 Oct; 124(1):33-41. PubMed ID: 22750480
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Occlusive paromomycin for cutaneous leishmaniasis.
    Bell SA; Schaller M; Röcken M
    Lancet; 1997 Jan; 349(9044):29. PubMed ID: 8988124
    [No Abstract]   [Full Text] [Related]  

  • 43. Combination therapy for visceral leishmaniasis.
    van Griensven J; Boelaert M
    Lancet; 2011 Feb; 377(9764):443-4. PubMed ID: 21255829
    [No Abstract]   [Full Text] [Related]  

  • 44. Development of topical treatment for cutaneous leishmaniasis caused by Leishmania major in experimental animals.
    El-On J; Jacobs GP; Witztum E; Greenblatt CL
    Antimicrob Agents Chemother; 1984 Nov; 26(5):745-51. PubMed ID: 6517557
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Leishmania aethiopica: topical treatment with paromomycin and methylbenzethonium chloride ointment.
    Weinrauch L; Katz M; el-On J
    J Am Acad Dermatol; 1987 Jun; 16(6):1268-70. PubMed ID: 3597872
    [No Abstract]   [Full Text] [Related]  

  • 46. Successful Treatment of Cutaneous Leishmaniasis with Topical Paramomycin in a Child After Treatment Failure with Systemic Fluconazole.
    Chacko A; Joseph M; Feltis T; Morris SK
    Am J Trop Med Hyg; 2016 Oct; 95(4):793-794. PubMed ID: 27549634
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial.
    Sundar S; Sinha PK; Rai M; Verma DK; Nawin K; Alam S; Chakravarty J; Vaillant M; Verma N; Pandey K; Kumari P; Lal CS; Arora R; Sharma B; Ellis S; Strub-Wourgaft N; Balasegaram M; Olliaro P; Das P; Modabber F
    Lancet; 2011 Feb; 377(9764):477-86. PubMed ID: 21255828
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Occlusive paromomycin for cutaneous leishmaniasis.
    Bryceson AD
    Lancet; 1997 May; 349(9063):1477. PubMed ID: 9164342
    [No Abstract]   [Full Text] [Related]  

  • 49. Unsuccessful treatment of cutaneous leishmaniasis by Leishmania infantum with topical paromomycin.
    Veraldi S; Benzecry Mancin V; Faraci AG; Nazzaro G
    Int J Dermatol; 2020 Jul; 59(7):e251-e252. PubMed ID: 31975375
    [No Abstract]   [Full Text] [Related]  

  • 50. Using focused pharmacovigilance for ensuring patient safety against antileishmanial drugs in Bangladesh's National Kala-azar Elimination Programme.
    Hossain MS; Kumar A; Hossain AFMA; Mahshin M; Sharma A; Hossain MA; Sharma V; Haque R; Shamsuzzaman AKM; Maruf S; Ghosh P; Ahuja V; Mondal D
    Infect Dis Poverty; 2018 Aug; 7(1):80. PubMed ID: 30099967
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cutaneous leishmaniasis treatment.
    Minodier P; Parola P
    Travel Med Infect Dis; 2007 May; 5(3):150-8. PubMed ID: 17448941
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Topical Treatment of Cutaneous Leishmaniasis in Israel, Part 1.
    Zur E
    Int J Pharm Compd; 2019; 23(3):200-207. PubMed ID: 31085788
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Randomized, double-blinded, phase 2 trial of WR 279,396 (paromomycin and gentamicin) for cutaneous leishmaniasis in Panama.
    Sosa N; Capitán Z; Nieto J; Nieto M; Calzada J; Paz H; Spadafora C; Kreishman-Deitrick M; Kopydlowski K; Ullman D; McCarthy WF; Ransom J; Berman J; Scott C; Grogl M
    Am J Trop Med Hyg; 2013 Sep; 89(3):557-563. PubMed ID: 23857024
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A randomized clinical trial of topical paromomycin versus oral ketoconazole for treating cutaneous leishmaniasis in Turkey.
    Ozgoztasi O; Baydar I
    Int J Dermatol; 1997 Jan; 36(1):61-3. PubMed ID: 9071622
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Topical Treatment of Cutaneous Leishmaniasis in Israel, Part 3.
    Zur E
    Int J Pharm Compd; 2019; 23(5):366-375. PubMed ID: 31513534
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Treatment of New World cutaneous and mucosal leishmaniases.
    Berman JD
    Clin Dermatol; 1996; 14(5):519-22. PubMed ID: 8889330
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Can a simple outpatient-based treatment be used to treat cutaneous leishmaniasis in young children? A Critically Appraised Topic.
    Burden-Teh E; Wootton CI; Williams HC
    Br J Dermatol; 2015 Apr; 172(4):861-6. PubMed ID: 25354137
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Evaluation of paromomycin sulphate topical ointment as effective therapeutic agent in cutaneous leishmaniasis.
    Sahibzada NJ; Tareen AK; Khursheed T; Darr N
    J Pak Med Assoc; 1996 Mar; 46(3):53-5. PubMed ID: 8991348
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Topical Paromomycin for treating solitary mucosal leishmaniasis.
    Kassem R; Peretz A; Porat Ben Amy D
    Int J Dermatol; 2018 Jun; 57(6):721-723. PubMed ID: 29377089
    [No Abstract]   [Full Text] [Related]  

  • 60. The lack of effectiveness of hyperbaric oxygenation as a treatment for Leishmania major in a mouse model.
    Livneh A; Youngster I; El-On Y; Berkovitch M; Abu-Kishk I
    Acta Parasitol; 2015 Jun; 60(2):345-9. PubMed ID: 26204005
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.